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Preface
An agreement has been signed by the Dutch Expert Committee for Occupational
Standards (DECOS) of the Dutch Health Council and the Swedish Criteria Group (SCG)
at the Swedish National Institute for Working Life. The purpose of the agreement is to
write joint scientific criteria documents for occupational exposure limits. Theses limits
will be developed separately by the two countries according to their different national
policies.
The evaluation of health effects of Cresols is a product of this agreement. The draft
document was written by Dr Hans Stouten from the Department of Occupational
Toxicology, TNO, Zeist, The Netherlands.  The document has been reviewed by the
Dutch Expert Committee as well as by the Swedish Criteria Group.
V.J. Feron J. Högberg
Chairman Chairman
DECOS SCG
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11. Introduction
Starting point in searching literature on the health effects of exposure to the cresol
isomers was the review by the US Agency for Toxic Substances and Disease
Registry (9). Unless otherwise indicated, data were derived from this document.
Data considered to be critical were evaluated by reviewing the original
publications. In addition, literature was retrieved from on-line databases Chemical
Abstract and Medline. The final search has been carried out in April, 1995 and
included Chemical Abstract 1995 vol 122/16 and Medline 950419/UP. Scientific
publications between 1995 and 1997 were no reason for adjustment of the
recommendations.
2. Identity, properties, and monitoring
2.1 Identity
2.1.1 Structure
CH3
OH
CH3
OH
CH3
OH
o-cresol                          m-cresol                          p-cresol
22.1.2 Chemical names and synonyms/registry numbers
name o-cresol m-cresol p-cresol
CAS number 95-48-7 108-39-4 106-44-5
CAS name phenol, 2-methyl- phenol, 3-methyl phenol, 4-methyl-
synonyms 2-cresol 3-cresol 4-cresol
o-cresylic acid m-cresylic acid p-cresylic acid
1-hydroxy-2- 1-hydroxy-3-methyl- 1-hydroxy-4-methyl-
methyl-benzene benzene benzene
o-hydroxytoluene m-hydroxytoluene p-hydroxytolunene
2-hydroxytoluene 3-hydroxytoluene 4-hydroxytoluene
o-methylphenol m-methylphenol p-methylphenol
2-methylphenol 3-methylphenol 4-methylphenol
o-oxytoluene m-oxytoluene p-oxytoluene
EINECS number 202-423-8 203-577-9 203-398-6
EEC number 604-004-00-9 id id
EEC labelling R: 24/25-34
S: (1/2-)36/39-45
EEC Classification T; R 24/25-34 for concentrations  5%
Xn; R 21/22-36/38 for concentrations 1%sC>5%
RTECS No GO6300000 GO6125000 GO6475000
2.2 Physical and chemical properties1
o-cresol m-cresol p-cresol
Molecular formula C7H8O id id
Molecular weight 108.14 id id
Boiling point (101.3 kPa) 191 oC 202.2 oC 201.9 oC
Melting point (101.3 kPa) 30.9 oC 11.5 oC 34.8 oC
Specific gravity, d204 1.0273 1.0336 1.0178
Vapour pressure (20 oC/101.3 kPa) 0.032 kPa (25 oC) 0.005 kPa 0.005 kPa
Percent in saturated air (101.3 kPa,
25 oC)
0.0323 0.0323 0.0142
Vapour density (air=1; 101.3 kPa) 3.72 id id
Flash point (closed cup) 81 oC 86 oC 86 oC
Solubility in water (25 oC) 26 mg/l 23 mg/l 22 mg/l
Solubility in organic solvents alcohol, ether,
acetone, benzene,
chloroform
id id
Partition coefficient log Kow 1.95 1.96 1.94
Physical form white crystals to
yellowish liquid
colourless to
yellowish liquid
crystalline solid to
yellowish liquid
Odour phenol-like id id
Odour threshold 0.65 ppm 0.00028 ppm 0.045 ppm
Conversion factors 1 mg/m3 = 0.22 ppm id id
(20 oC, 101.3 kPa) 1 ppm = 4.50 mg/m3 id id
1Data from: refs 9, 18, 27, 56, 70
3Apart from the pure isomer forms, cresol is commercially available as a mixture
of isomers contaminated with small amounts of phenol and xylenols. This mixture
(CAS registry number: 1319-77-3; synonyms: cresylic acid, tricresol) is a
colourless to yellowish or pinkish liquid with a phenolic odour (bp: 191-203 oC;
mp: 11-25 oC) and soluble in alcohol, glycol, and dilute alkalies. Lysol is a
generic name for a 50% (v/v) solution of cresol in a saponaceous solvent (44). In
The Netherlands, "Asepta Creoline pura" (89 g "kresol" per l), "Asepta
Kresolzeep" (434 g "kresol" per l), and "Kresolzeepoplossing D.H." (434 g
"kresol" per l) are trade names of cresol-containing products regulated for
disinfectant purposes (24).
The cresols form a number of binary and ternary azeotropic mixtures.
2.3 Validated analytical methods
2.3.1 Environmental monitoring
NIOSH method 2001: This method is suitable for measuring total cresol isomers.
These are adsorbed to silica gel, desorbed with acetone, and analysed gas
chromatographically using FID. The overall precision is 6.8% at a concentration
range of 10-42 mg/m3; the limit of detection has not been determined. The
working range is 5-60 mg/m3 for a 20-l air sample. Since silica gel has a great
affinity for water, its capacity will be greatly reduced at high humidity (40).
OSHA method 32: This method is suitable for phenol and cresols. These
compounds are adsorbed to XAD-7 resin, desorbed with methanol, and analysed
using HPLC with UV detection. The cresol isomers are not separated by this
method. The limit of detection is 0.046 mg/m3. Alternatively, gas chromatography
using FID can be used to detect the cresols. This detection method is reported to
be less sensitive, but it separates the isomers (66).
Infrared spectroscopy: The cresol isomers can be detected with infrared
analysers at a wavelength of 8.6 m m at a minimum concentration of 1.8 mg/m3
(41). This method does not separate the isomers, and can only be used when no
other chemicals are present which absorb at the same wavelength.
In addition, a number of liquid (54, 63) and gas (23, 59) chromatographical
methods for the detection of the (individual) cresol isomers in workplace or
environmental air have been proposed.
2.3.2 Biological monitoring
NIOSH method 8305: This method includes acid hydrolysis and diethyl ether
extraction. The samples are analysed gas chromatographically using FID. The
limit of detection is 0.5 mg/l urine. According to NIOSH, this method is suitable
for measuring phenol and p-cresol in urine, and is useful in screening workers
exposed to phenol, benzene, and p-cresol. It was noted that phenol and p-cresol
occur normally in urine (see also Section 5.5) (40). This background occurrence
of phenol and p-cresol in urine may complicate biological monitoring in practice.
DFG has published a method by which phenols and aromatic alcohols can be
determined in urine. This method uses capillary gas chromatography using FID;
4m- and p-cresol could not be separated completely. The limit of detection is 0.3
mg/l urine (7).
Several other methods for the detection of the (individual) cresol isomers in
urine have been presented including gas (60), liquid (HPLC) (11, 28, 29, 84), and
thin layer (+ UV spectroscopy) (14) chromatography.
3. Sources
3.1 Natural occurrence
Cresols are formed in air due to photochemical reactions between toluene and
photochemically generated hydroxy radicals (but may disappear by similar
reactions as well). Being combustion products, they may be released into the
atmosphere by natural fires associated with lightning, spontaneous combustion,
and vulcano activity.
Furthermore, cresols are metabolites of microbial activity and excreted in the
urine and manure of mammals and poultry. They occur in various plant lipid
fractions, including many oils (9).
3.2 Man-made sources
Cresols are distributed into the environment not only from natural, but also from
anthropogenic sources. Most of these are related to combustion processes (coal,
wood, municipal solid waste, gasoline and diesel fuels, cigarettes). They have
been found in certain foods and beverages (9, 57).
3.2.1 Production
Initially, cresols were produced by fractional distillation of coal tars and by
catalytic and thermal cracking of naphtha fractions. Later, in the 1960s, when
these sources were not sufficient to meet rising demands, other processes to
produce cresol isomers were developed: methylation of phenol (o-cresol), the
toluene sulphonation process (p-cresol), the cymene-cresol process (m-, p-cresol),
the alkaline chlorotoluene hydrolysis (mixture with a high m-cresol content) (9).
3.2.2 Uses
o-Cresol is used as a solvent and as a disinfectant. Furthermore, it is an inter-
mediate for a wide variety of products: solvents, deodorising/odour-enhancing
agents, antiseptics, fragrances, antioxidants, dyes, resins, pesticides.
m-Cresol is an intermediate for the production of herbicides and insecticides, of
several important antioxidants, and of explosives. It is applied in the fragrance and
flavour industries.
p-Cresol is used in the formulation of antioxidants, and is applied in the
fragrance, flavour, and dye industries.
5Mixtures of m- and p-cresol are used to produce herbicides, and as disinfectants
and preservatives. These mixtures are intermediates for phosphate esters which
are used as flame-retardant plasticisers, fire-resistant hydraulic fluids, additives
for lubricants, and air filter oils.
Cresol mixtures are used in modifying phenolic resins, in paints, in textiles, as
solvents for synthetic resin coatings (wire enamel), as metal degreasers, cutting
oils, removing agents (carbon deposits from combustion engines), and in ore
flotation and fiber treatment. Crude cresols are also used as wood preservatives
(9).
4. Exposure
4.1 General population
4.1.1 Air
In the Netherlands, emissions from industrial companies with more than ten
employees have been registered per province. Total process emissions registered
in the period 1974 to 1982 amounted to approximately 260 tonnes per year (74).
Corresponding figures for the periods 1981-1984, 1985-1987, and for 1988 and
1990 105, 54 and 43 (for both 1988 and 1990) tonnes per year. m-Cresol
accounted for about 95% during the period 1985-1987 and for more than 99.5%
of the emissionsduring the other periods (12).  According to information of the US
Toxic Chemicals Release Inventory, an estimated amount of approximately
430 tonnes were released in 1987 by about 90% of the 160 cresols manufacturing
or processing facilities (9).
There are hardly any specific data, probably because the cresols are very
reactive with hydroxyl and nitrate radicals resulting in short atmospheric half-
lives. Only data on o-cresol were reported, coming from a US database consisting
of published and unpublished data on ambient volatile organic compounds
monitored in the period 1970 to 1987. The mean air concentration from
atmospheres surrounding facilities or known releases of o-cresol were reported to
be approximately 0.4 ppb (from 32 samples) (9).
4.1.2 Water
Although the cresols occur widely, natural and anthropogenetic products data on
its presence in water are scarce, probably because of their rapid removal by
biodegradation. Two US databases did not contain records for o-cresol in ambient
surface waters. m-Cresol and p-cresol were detected at a very low frequency of
occurrence (0.9 and 1.5%, respectively) at amounts in the lower mg/l range.
Groundwater levels may be higher; a maximum level of 100 mg/l for m-cresol is
reported. Rainwater may also contain small amounts of cresols (less than10 mg/l)
(9).
64.1.3 Other
The cresol isomers, alone or in combination, have been detected in a variety of
food products. Amongst others, asparagus (raw, cooked), Lamb's lettuce, wild
rice, (peated) malt, boiled eggs, smoked fatty fish, cuttlefish, and curred pork
(boiled, cooked, fried, smoked) contained all three isomers, while m- and p-cresol
were found in (amongst others) milk and butter. As far as quantitative data were
presented, concentrations generally did not exceed 10 mg/kg except for smoked
products (such as smoked fatty fish and smoked pork) for which levels of up to 2
mg/kg (m-cresol in fish) were reported. Beverages such as beer, cognac, rum,
whisky, wine, coffee, tea, and passion fruit juice contained all three isomers,
generally at levels less than 100 mg/l, except for coffee for which levels of
approximately 13 mg/l were reported (57).
The total concentration of cresols in cigarette smoke was reported to be 7.5 fg
per cigarette, resulting in a daily amount inhaled of 1.5 mg at smoking one pack a
day (9).
4.2 Working population
In Sweden, the use of o-, m-, and p-cresol amounted to 31-32, 126-143, and 12-18
tonnes, respectively, in 1994; for cresols (undefined), a use of 599-666 tonnes was
reported (U Rick, Swedish National Chemicals Inspectorate, 1996; personal
communication). There are hardly any data on cresol concentrations in workplace
air, possibly because cresols are of low volatility (70).
No cresols were detected in eight personal and four area five- to eight-hour air
samples at a lubricating oils and waxes producing refinery (limit of detection: 10-
20 mg/sample) (48). In two Finnish plants using creosote to impregnate wood,
breathing zone air levels of cresols (components of creosote vapour) were below
0.1 mg/m3 (0.02 ppm), but short peak levels of up to 0.6 mg/m3 (0.13 ppm) were
recorded during certain activities (46). In a bench scale coal conversion process,
cresol air levels were less than 0.05 mg/m3 (0,01 ppm) (data from 1981, 1982) (9).
Data on occupational exposure levels in Sweden have not been found (U Rick,
Swedish National Chemicals Inspectorate, 1996; personal communication).
5. Kinetics
5.1 Absorption
5.1.1 Pulmonary
No quantitative information was found on the pulmonary absorption of the cresol
isomers in humans or animals.
5.1.2 Percutaneous
No quantitative information on the percutaneous in vivo absorption of the cresol
isomers in humans or animals was found. From human and animal toxicity data, it
7can be seen that the cresols may readily be absorbed through the skin (probably
facilitated by their skin damaging properties).
In vitro, the percutaneous penetration of a number of para-substituted phenols,
including p-cresol, has been measured by applying 4 mg/cm2 of labelled
compound (in acetone) to hairless mouse stratum corneum (surface 3.1 cm2) in a
diffusion cell. The receptor solution was pH 7.4 phosphate-buffered normal saline.
The cumulative absorption of p-cresol was 69 –  6, 74 –  4, and 77 –  3 % of the
dose after 6, 12, and 24 hours, respectively; the maximum flux was reached after 2
h and amounted 25 –  3.9 % per hour (49). These data indicate that under these
experimental conditions p-cresol readily penetrates mouse skin. However, it is not
possible to calculate a human skin penetration rate from these data, since it is not
known how to extrapolate these in vitro mouse data to occupational exposure of
human skin.
5.1.3 Oral
In rabbits, roughly 75-90% of orally administered (gavage) doses of 100 or
200 mg/kg of the single isomers was excreted in the urine within 24 hours (17),
indicating an almost complete absorption from the gastrointestinal tract.
5.2 Distribution
No data were found.
5.3 Biotransformation
No human data were found.
In vivo animal data are limited to results from experiments with rabbits: the
single cresols were mainly converted to O-conjugates (60-70% glucuronides; 10-
15% sulphates) following oral administration (gavage). Minor metabolites from o-
and m-cresol included conjugated 2,5-dihydroxytoluene (less than 3 %), and free
and conjugated p-hydroxybenzoic acid (about 7 % and less than 3 %, respectively)
and in the case of p-cresol traces of 3,4-dihydroxytoluene (17).
In vitro experiments using rat liver microsomes showed that oxidative
metabolism of p-cresol may proceed differently from that of the other isomers,
i.e., through the formation of a reactive quinone methide intermediate which can
be trapped by glutathione (75, 76) (see also Section 6.3).
5.4 Excretion
No human data were found.
As mentioned in the previous section, only oral rabbit data are available. The
primary excretory route is urinary excretion, O-conjugates being the most
important constituents accounting for 60-70% of the administered dose (17).
The possibility of undergoing enterohepatic circulation was mentioned by Dietz
(35), but in view of the rabbit biotransformation data (see Section 5.3) and the
8relatively low molecular weight of the cresol glucuronides [276] this is not very
likely to occur to a great extent.
5.5 Biological monitoring
There are no data available to adequately evaluate possibilities for monitoring
workers exposed to cresols.
Measuring the single cresols in the urine may be an option. However, it should
be recognised that non-occupational exposure to cresols may occur. p-Cresol is an
intestinal bacterial degradation product of amino acids, and is found in the excreta
of normal individuals. Average normal urine values of 50 and 90 mg/l and a range
of 20-200 mg/l have been reported (7, 11). As to faeces, no data on adults were
found, but 4- to 11-year-old "normal" children excreted 58.5 mg/g faeces, and
"hyperactive" children of the same age 243.2 mg/g (3).
In addition, cresols are urinary excreted metabolites of toluene.
5.6 Summary
There are no data on the absorption of cresols via the various exposure routes by
humans. They may readily penetrate the skin of man and animals in vivo, but this
cannot be quantified.
In vivo animal data are limited to those from a rabbit gavage study. These data
indicate that roughly 75-90% of the administered dose is absorbed from the
gastrointestinal tract and excreted in the urine, mainly as O-conjugates (60-70%
glucuronides, 10-15% sulphates). Data from in vivo studies using rabbits and from
in vitro studies using rat liver microsomes suggest that oxidative metabolism of p-
cresol proceeds differently from that of the other isomers.
There are no data to evaluate possibilities for biological monitoring.
6. Effects
6.1 Observations in man
6.1.1 Irritation and sensitisation
ATSDR (9) and NIOSH (64) refer to a Russian study in which concentrated
aerosols of o-cresol were found irritative to the human respiratory tract and in
which brief exposures to 6 mg/m3 (1.4 ppm) caused mucosal irritation in eight out
of ten volunteers. Exposure level, exposure duration and purity of the chemical
were not reported
Dermal exposure to cresols may result in severe skin irritation (corrosion,
burns) and dermatitis (1, 68). The cresols are considered to be severe eye irritants
as well (55).
96.1.2 Toxicity due to acute and short-term exposure
No data on systemic effects following acute and short-term occupational exposure
to cresol vapours or aerosols were located.
6.1.3 Case reports and/epidemiological studies
No epidemiological studies or case reports on occupational exposure to cresols
were found containing adequate details on exposure levels, etc. NIOSH (64) refers
to reports from decades ago in which workers exposed to unknown concentrations
of cresols in combination with unknown concentrations of other chemicals
(formaldehyde, ammonia, phenols) suffered from nervous system and vascular
disturbances.
Women in the former Soviet Union engaged in the manufacture of enamel-
insulated wires or tricresylphosphate and occupational exposed to tricresol and
other compounds such as chlorobenzene and phosphoryl chloride were reported to
have menstrual disorders, hormonal disturbances, increased frequency of perinatal
mortality, and increased abnormal development of newborns. However, no data
on exposure levels, exposure duration or employment duration, presence of other
compounds, control groups, etc, were presented (13, 35, 43).
Based on its excretion in urine, endogenous p-cresol was concluded not to
contribute significantly to the development of human bladder cancer (32 patients
vs 32 age-/sex-matched controls) (69) or large bowel cancer (18 patients vs 10
normal healthy persons) (15).
There are numerous case reports describing effects following intentional or
accidental ingestion of cresols. These effects include irritation of mouth and
throat, abdominal pain and vomiting, tachycardia and ventricular fibrillation,
haemolytic anaemia, liver and kidney damage, facial paraesthesia, headache,
dizziness, convulsions, coma, and death (9, 64, 68). In addition, (heavy) dermal
exposure due to spilling or immersing hands for hours produced effects on the
central nervous system, liver, kidneys, and vascular system, and was lethal (9, 64).
6.2 Animal experiments
6.2.1 Irritation and sensitisation
When instilled into the eyes of rabbits according to the Draize method, maximum
scores ranging from 87.3/110 to 93.0/110 (depending on the isomer tested) were
obtained (13), indicating that the individual cresol isomers are severely irritating
to the eyes of rabbits (30). (according to the Texaco classification system: Draize
score 0-15: minimally; >15-25:slightly; >25-50: moderately; >50-80: severely;
>80-110: extremely irritating) From an unpublished German study, m-cresol was
concluded to be highly irritant to the eyes of rabbits (13).
The individual cresol isomers and a mixture of these were highly irritating
causing corrosion when applied to the shaved backs and flanks of rabbits (patch
testing for 4 h) (80). In an unpublished study, similar results were reported for the
separate cresol isomers when tested under occlusion for 24 hours (13). 
Application of unreported amounts of 0.5 % p-cresol in acetone to an epilated
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or clipped area of the backs of mice, three times weekly for six weeks resulted in
depigmentation of the skin and hair, while the other isomers did not show such an
effect (73).
Using a modified Draize procedure (administration of total dose on one
occasion as four intradermal injections, each 2.5 times the injection challenge
concentration (ICC) instead of administration of this dose by ten injections at the
ICC over a three-week period), p-cresol did not induce sensitisation in guinea pigs
(injection challenge concentration: 0.1%; application challenge concentration:
10%) (72). In a Russian study in which a 7.5% solution of a mixture of m- and p-
cresol in acetone was repeatedly applied to the skin of guinea pigs, sensitisation
was not observed (13).
In repeated dose feeding studies, mainly p-cresol and a mixture of m- and p-
cresol induced histopathological changes in the nasal cavity (see Sections 6.2.3
and 6.2.4). These lesions may have been the result of either direct contact of the
nose with the compounds in the feed or of exposure to their emanating vapours.
In an inhalation study reported in Russian, respiratory tract irritation has been
found in mice, rats, and cats following acute and short-term exposure to concen-
trations of an o-cresol vapour/aerosol mixture ranging from 5-10 to 178 mg/m3
(13).
In conclusion the cresol isomers and their mixtures are extremely irritating to
the skin and eyes of rabbits. p-Cresol and a m-/p-cresol mixture are not skin
sensitisers when tested in guinea pigs.
6.2.2 Toxicity due to acute exposure
In an unpublished US study, it was reported that exposure to (theoretically)
maximum concentrations (calculated to be 1220 and 710 mg/m3 for o- and m-/p-
cresol, respectively) for one hour was not lethal to rats during the observation
period of 14 d after the exposure. In other reports, mean lethal concentrations of
29-58 and 178 mg/m3 were presented for rats and mice, respectively (exposure
periods and other relevant data not available). In mice, signs of toxicity included
muscle twitching progressing to clonic convulsions, haematuria, and necrotic and
degenerative changes in the lung and liver (as well as respiratory tract irritation;
see Section 6.2.1) (13).
Other data on lethality following single exposure to the separate cresol isomers
are presented in Table 1. From these data, it may be concluded that m-cresol is the
less (lethally) toxic isomer, and that the cresol isomers are more toxic via the
dermal route than via the oral route. It is not known to which extent the corrosive
properties play a role as to this difference.
I.p. injection of 200 mg/kg bw o- or m-cresol or of 75 mg/kg p-cresol produced
lethargy, piloerection, and lacrimation in mice within 21.5 hours in an experiment
designed to study in vivo mutagenicity (22). In a separate experiment, the ip dose
inducing convulsions such as myoclonic jerks of limbs and tail in 50% of the mice
injected was calculated to be 117, 102, and 110 mg/kg bw for o-, m-, and p-cresol,
respectively (6). I.v. infusion of o-cresol (0.9 mg/min, 15 min: total dose: 50-60
mg/kg bw) caused excitation of the somatosensory evoked potential and EEG of
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Table 1. Acute lethal toxicity data of o-, m-, and p-cresol
Species Route Dose (mg/kg bw) Parameter Reference
ortho meta para
rat oral 1350 2020 1800 LD50 26
oral 1470 2010 1460 LD50 64
oral 121 242 207 LD50 19
dermal 620 1100 750 LD50 19
s.c. 65 900 500 LDLo 19
mouse oral 344 828 344 LD50 19
s.c. 410 450 150 LDLo 19
i.p. 168 25 LD50 19
i.p. 200 LDLo 19
rabbit oral 940 1400 620 LDLo 19
dermal 890 2830 300 LD50 81
dermal 1380 2050 301 LD50 64
s.c. 450 500 300 LDLo 26
i.v. 180 280 180 LDLo 26
guinea pig s.c. 35 300 200 LDLo 19
i.p. 720 100  LDLo 19
dog i.v. 80 150 LDLo 19
cat s.c. 55 180 80 LDLo 26
LDLo: lowest published lethal dose; s.c.:subcutaneous; i.p.: intraperitoneal; i.v.: intravenous
rats; these rats were hyperresponsive to stimuli. If exposure was sufficiently great
(duration not reported), involuntary muscle movements and tremors developed
(58).
6.2.3 Toxicity due to subacute exposure
In an inhalation study reported in Russian, respiratory irritation (initially) and
hypoactivity (later) were observed in mice exposed to concentrations of an o-
cresol vapour/aerosol mixture ranging from 26 to 76 mg/m3 (average 50 mg/m3), 3
h/d, 6 d/w, for one month. Body weight gain was slightly reduced. Microscopical
examination showed signs of respiratory tract irritation and degenerative changes
in the heart muscle, liver, kidney, and CNS (13).
Dietz examined the effects of o-, m-, and p-cresol, and of a 60:40% mixture of
m- and p-cresol (choosen because of being comparable to the cresols mixture
prepared from coal tar) by feeding F344/N rats and B6C3F1 mice 0, 300, 1000,
3000, 10,000, and 30,000 mg per kg feed for 28 days; all study groups consisted
of 5 animals of each sex The study protocol included twice-daily observations of
the animals for signs of toxicity, weekly recording of body weight and twice
weekly recording of feed consumption (water consumption was not registered),
necropsy of all animals at termination and collection of their tissues, recording of
organ weights  of i.e., brain, heart, right kidney, liver, lungs, thymus for all
animals, as well as of the right testis for all male animals, complete microscopical
examination of all control animals, all animals in the highest dose group with at
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least 60% survivors at termination, and all animals in higher dose groups inclusive
of early deaths, and examination of target organs and of gross lesions at lower
doses until a no-observed chemical effect level was determined (35).
The results of these studies are presented in the Annex, and will be briefly
discussed below.
o-Cresol. No rats died during the study; neither clinical signs of toxicity nor
gross lesions were observed. An initial decrease in feed consumption was
observed in the 30,000 mg/kg feed group probably due to poor palability.
Exposure resulted in body weight (gain) changes and (relative) organ weight
changes without accompanying histopathological changes.
In conclusion, this 28-day study feeding o-cresol to rats resulted in a NOAEL of
1000 ppm (i.e., 87 mg/kg/d) and an effect level (increased relative liver and
kidney weights) of 3000 ppm (i.e., 266 mg/kg/d)  for male animals, and in a
NOAEL of 3000 ppm (i.e., 271 mg/kg/d) and an effect level (increased relative
liver weight) of 10,000 ppm (i.e., 881 mg/kg/d) for female animals.
As to mice, in the highest dose group, three animals died or were sacrificed
moribund, without showing histopathological changes; clinical signs of toxicity
were observed. Furthermore, body weight (gain) and organ weights were affected
similarly to rats. Necropsy did not show gross lesions, but at microscopical
evaluation, ovarian and uterine atrophy were observed.
This 28-day study feeding o-cresol to mice resulted in a NOAEL of 87 mg/kg
bw/d and a level at which relative liver  weights were increased of 266 mg/kg
bw/d for male animals, and in a NOAEL of 271 mg/kg bw/d and a level at which
relative liver weights was increased 881 mg/kg bw/d for female animals.
m-Cresol. In rats, exposure did neither result in mortality, nor in clinical signs
of toxicity. Parameters affected included feed consumption due to poor
palatability, body weight (gain), (relative) organ weight (without accompanying
microscopical lesions). Furthermore, minimal to mild uterine atrophy was
observed.
This 28-day study feeding m-cresol to rats resulted in a NOAEL of 252 mg/kg
bw/d for male and female animals and a level at which absolute (in male) and
relative liver weights (in male and female animals) were increased of 870 mg/kg
bw/d for male and 862 mg/kg bw/d for female animals.
In mice, exposure resulted in mortality without accompanying histopathological
changes. Other effects were similar to those found in rats.
This 28-day study, feeding m-cresol to mice resulted in a NOAEL of 193 mg/kg
bw/d and an effect level (increased relative liver and kidney weights) of 521
mg/kg bw/d in male animals. No NOAEL was found in female animals since at
the lowest dose tested (66 mg/kg bw/d) relative liver weights were increased.
p-Cresol. In rats, clinical signs of toxicity were observed, and histopathological
changes in bone marrow and nose were found. The other effects noted were
similar to those seen following exposure to the other isomers. This 28-day study
feeding p-cresol to rats resulted in a NOAEL of 87 mg/kg bwD for male and of 83
mg/kg bw/d for female and a level at which mild bone marrow hypocellularity (in
1/5 male) and absolute and relative liver weights in female animals were increased
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of 256 mg/kg bw/d for male and of 242 mg/kg bw/d for female animals. The
microscopical nasal epithelial lesions were not considered to be systemic effects
following oral uptake, but may have been the result of direct contact of the nose
with p-cresol in the feed or of exposure tocresol vapors emanating from the feed.
In mice, exposure to the high dose caused the death of all animals. Effects in the
other dose groups were similar to those seen following exposure to the other
isomers. The increased absolute brain weights in females were considered to be
minimal and accidental findings when comparing them with those found in the
experiments with other isomers. This 28-day study feeding p-cresol to mice
resulted in a NOAEL of 163 mg/kg bw/d for male and of 207 mg/kg bw/d for
female animals. The level at which relative kidney weight (in males). relative liver
weight (in females) were increased, was 469 mg/kg bw/d for males and 564
mg/kg bw/d for females. As in the rat study the nasal lesions were not considered
to be signs of oral systemic toxicity (see rat study).
m/p Cresol. Feeding a 60:40% mixture of m- and p-cresol resulted in similar
systemic effects. In addition, irritating effects on nasal epithelium and on oeso-
phagus and forestomach were seen in rats and mice (mainly on the nose). In rats,
90 mg/kg bw/d is concluded to be the NOAEL for male animals, while 261 mg/kg
bw/d is a level at which relative liver weight and histopathological changes in
thyroid were increased; for female animals, 27 mg/kg bw/d is the NOAEL and
Table 2. Summary of 28 days study by Dietz (35).
NOAEL
mg/kg bw
LOAEL
mg/kg bw
Effect
Ortho- rat male   87 266 Increased relative liver weight
female 252 881 Increased relative liver weight
mouse male 193 558 Increased relative liver weight
female 280 763 Increased relative liver weight
Meta- rat male 252 867 Increased relative and absolute liver
weight
female 252 862 Increased relative liver weight
mouse male 193 521 Increased relative liver and kidney
weight
female <66   66 Increased relative liver weight
Para- rat male   87 256 Bone marrow hypocellularity
female   83 242 Increased relative and absolute liver
weight
mouse male 163 469 Increased relative kidney weight
female 207 564 Increased relative liver weight
m/p rat male   90 261 Increased rel liver weight; hist changes
thyroid
female   27   95 Increased relative and absolute liver
weight
mouse male 50 161 Increased relative liver weight
female 200 604 Increased relative and absolute liver
weight
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95 mg/kg bw/d a level at which relative and absolute liver weight were increased.
In mice, 50 mg/kg bw/ was the NOAEL for male animals; effects were noted at
161 mg/kg bw/d (increased relative liver weight). For female animals, the
NOAEL is 200 mg/kg bw/d while 604 mg/kg bw is an effect level (increased
absolute and relative liver weight).
In conclusion, the NOAELs and LOAELs and related effects resulting from the
studies by Dietz (35) in which rats and mice were fed 300-30,000 mg/kg feed of
cresols (separate isomers; 60:40% m/p mixture) for 28 days can be summarised as
follows in Table 2.
Furthermore, p-cresol and the m-/p-mixture caused local irritating effects of the
nose and of the oesophagus and forestomach (mixture only) in both species. Apart
from these localized effects, there are no indications to make a distinction between
the effects induced by the separate isomers and the mixture. The NOAEL found in
the m/p cresol study of 27 mg/kg bw/d can be taken as the NOAEL for all cresol
isomers or any mixture in rats. In mice, no NOAEL could be established from the
Dietz data: administration of 66 mg/kg bw/d of m-cresol, the lowest dose tested,
increased the relative liver weights of male animals.
6.2.4 Toxicity due to subchronic exposure
The only subchronic inhalation studies available are reported in Russian and
discussed in reviews. They do not allow a proper assessment of toxicity due to
poor reporting of the inhalatory exposure. However, they show that intermittent
exposure (4-6 h/d, 5 d/w) to low levels of vapours/aerosols of separate cresol
isomers or mixtures of them (5-10 mg/m3), for four months, induces respiratory
tract and eye irritation, and effects on the nervous system, liver, lung, kidney,
growth, and blood in rats. Only minor haematological changes and slight effects
on the nerve pulses were seen in guinea pigs (9, 13).
Current criteria concerning toxicity testing are met much better by the available
oral (gavage, feeding) studies.
o-Cresol. Rats (F344/N; n=20/sex/group) were fed 0, 1880, 3750, 7500, 15,000,
or 30,000 mg per kg feed ( »  130-2025 mg/kg bw/d, calculated by the author of the
study from recorded food consumption and body weights) of o-cresol in the diet
for thirteen weeks. The protocol of this study was similar to that of the 28-day
feeding studies (see page 12). In addition, microscopical examination of the bone
marrow for lower dose groups, haematological, clinical chemistry, and urinalysis
determinations, and sperm morphology and vaginal cytology examinations were
included. All rats survived, and they did not show clinical signs of toxicity. In the
male animals of the highest dose group and in the female animals of the two
highest dose groups, mean final body weights and mean final body weight gain
were statistically significantly decreased when compared with those of controls.
During the first week of study, feed intake was decreased for the high-dose
animals. Relative and absolute organ weights (liver, kidney, thymus, testis) were
affected in the highest or two highest dose groups; increased absolute and relative
liver weight already occurred at 7500  mg/kg feed. Apart from increased
concentrations in total bile acids in serum up to experimental day 43 in male and
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female animals of the two highest dose groups, no changes in haematology,
clinical chemistry, and urinalysis parameters were noted. At microscopical
examination, minimal to mild bone marrow hypocellularity was seen in the male
animals of the highest dose group and in the female animals of the two highest
dose groups, but this was considered to be secondary to decreased weight gain.
With respect to the reproductive tissue endpoints, reproductive tissue weights and
spermatozoal characteristics were not changed, but in the female animals oestrus
cycle was dose-relatedly increased in the 7500- and 30,000-mg/kg feed groups
(not statistically significant; not determined in the 3750- and 15.000 mg per kg
feed group) (35).
In conclusion, this thirteen-week study feeding o-cresol to rats resulted for both
sexes in a NOAEL of 250 mg/kg bw/d and an effect level (increased absolute and
relative liver weights) of 510 mg/kg bw/d.
In another study rats (Sprague Dawley; n=30/sex/group) were given daily oral
(gavage) doses of 0, 35, 175, and 600 mg/kg feed of o-cresol in corn oil for
thirteen weeks, and were sacrificed at week 7 (n=10/sex/ group) or week 14 (end
of experiment). Investigations and observations included haematology, clinical
chemistry, and urinalysis parameters, clinical signs, body weight, body weight
gain, food consumption, ophthalmology, gross necropsy, organ weights (heart,
liver, spleen, kidneys, testes, ovaries, adrenals, brain, thyroid), and histopathology
(except for low dose group). Treatment-related effects were limited to the high
dose group (except for reversible CNS depression - lethargy, tremors, coma - in
two mid-dose female animals on one occasion). Nineteen female and nine male
animals died, mainly in the first half of the study. Frequently, signs of CNS
depression (lethargy, tremors, dyspnea, convulsions, coma) were observed post-
dosing (mostly disappearing within 1 h) and at the weekly physical examinations
(particularly in the first 4-5 w, and again at week 9 and 10). At necropsy, no
histopathological changes were found. The lung lesions observed were ascribed to
aspiration following convulsions. No target organ could be indicated. Besides
statistically significant reductions in body weight (after test w 1-9), body weight
gain (w 1-9), and food consumption (w 1-6, 9) in male animals only, no other
effects were seen (32).
In conclusion  , this thirteen week study in which o-cresol was administered by
gavage to rats resulted in a NOAEL of 175 mg/kg bw/d for both male and female
animals.
In a separate study, the neurotoxicity of o-cresol has been examined by
administering 0, 50, 175, 450, or 600 mg/kg feed by gavage to Sprague-Dawley
rats of both sexes (n=10/sex/group; controls: n=20/sex/group) for thirteen weeks.
Observations for mortality and clinical effects were made twice daily (for 1 h
following dosing and approx 4 h after dosing), while body weight and feed
consumption were recorded weekly. Neurotoxic examinations included hindlimb
spray, toe/tail pinch, limb rotation, positive geotropism, forelimb grip strength,
wire manoeuvre, startle response, locomotor activity, positional passivity,
impaired gait, rales, laboured respiration, respiration rate, palpebral closure,
vocalisation, lacrimation, pupil size, diarrhea, piloerection, tremors, urination and
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salivation. The examinations were conducted before treatment, one hour and six
hours after dosing on day 1 and prior to dosing on days 2, 7, 14, 30, 60, and 90.
Finally, animals were selected for gross and microscopical examination of the
brain and nervous system tissues. At 600 mg/kg feed, mortality was 4/10 male (2
direct compound-related; 1 from aspiration; 1 from pulmonary oedema) and 7/10
female animals (5 direct compound-related; 1 not ascertained; 1 not compound-
related, for due to ascites of renal origin); at 450 mg/kg, there were two deaths:
one male rat died due to pulmonary oedema, while the death of one female animal
could not be ascertained. Exposure did not affect mean group body weights. The
mean group food consumption was decreased in the male animals of the two
higher dose groups, but only during week 1. There were no gross or microscopical
lesions in the brain or nervous system tissues. No primary compound-related
effects were observed in the neurobehavioural tests. Observations made within the
framework of the neurotoxic examinations showed increased incidences only for a
few of these parameters, up to 24 hours after the first dosing at most, at 600 mg/kg
feed. At the twice-daily observations, there were dose-related increases (>5%) in
incidences of salivation, hypoactivity, myotonus, tremors, urine-wet abdomen,
and rapid respiration. These incidences were lower at the afternoon observations.
These signs were absent or sporadicly  (less than 30 x on a total of 910
observations) seen in the two lower dose groups (77).
In conclusion, this thirteen week gavage neurotoxicity study in rats resulted in a
NOAEL of 175 mg/kg bw/d for both male and female rats.
In a two-generation reproduction study (see Section 6.2.7) in which male and
female F0 rats were exposed for thirteen (males) to about nineteen (females)
weeks by gavage, no clinical signs such as hypoactivity, laboured and audible
respiration, etc, were seen in these parental F0 animals at a dose level of 175
mg/kg bw/d, while exposure to 450 mg/kg bw/d resulted in mortality and a
number of CNS-related clinical signs (hypoactivity, ataxia, tremors, etc) of which
only laboured respiration was persistent. The F1 adults appeared to be more
sensitive, since effects were observed at 175 mg/kg bw/d, but not at 30 mg/kg
bw/d (80). In conclusion, in this two-generation reproduction study in which o-
cresol was administered by gavage for thirteen (males) to about nineteen
(females) weeks, a NOAEL of 175 mg/kg bw/d for paternal and maternal F0
toxicity can be derived.
Given 0.3 g/l o-cresol in the drinking water of rats for up to twenty weeks
(cumulative dose: 5028 mg/kg, i.e., » 36 mg/kg bw/d) caused small changes in
some biochemical parameters measured in brain homogenates and glial cells (71).
Since only one dose was tested and since the biological significance of these small
effects with respect to the health of workers is not clear yet, no conclusions can be
drawn from this experiment.
Mice (B6C3F1; n=10/sex/group) were fed diets containing 0, 1250, 2500, 5000,
10,000, or 20,000 mg/kg feed (i.e., male 199-2723 mg/kg bw/d, female 237-3205
mg/kg bw/d, calculated by the author of the study from recorded food
consumption and body weights) for thirteen weeks. The study design was similar
to that presented above for F344/N rats (35) except that the forestomach,
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considered to be a target organ, was examined microscopically at lower dose
levels. All mice survived treatment. Clinical signs, i.e., hunched posture and rough
hair coat, were observed in all male animals of the highest dose group. There was
a significant decrease in mean final body weight in the male animals of the
highest dose group and in the female animals of the three highest dose groups.
Body weight gain was depressed in the male animals of all dose groups except the
2500 mg/kg feed group and in the female animals of the three highest dose
groups. Feed consumption was lowered during the first week in the highest dose
group. Relative organ weights (kidney, thymus, testis) were changed in the higher
dose groups; the relative liver weight was increased in the male animals of all
dose groups (and in the female animals of the three highest dose groups). There
were hardly any changes in haematology, clinical chemistry, and urinalysis
parameters: the increases in serum levels of alanine aminotransferase and
5'-nucleotidase at experimental day 90 in the female animals of the highest dose
group were considered biologically insignificant, since they were not
accompanied by histopathological changes. Minimal forestomach and oesophagus
epithelial hyperplasia observed in some animals in the highest dose group was felt
to be a primary irritant effect. There were no treatment-related changes in male
reproductive endpoints, but in the highest dose group the oestrus cycle was
lengthened (35).
In conclusion, from this thirteen-week study feeding o-cresol to mice, no
NOAEL can be established for male animals, since administration of 1250 ppm
(199 mg/kg/d), the lowest dose tested, caused an increase in relative liver weight.
For female animals, the NOAEL is 496 mg/kg bw/d while 935 mg/kg bw/d) is an
effect level (increased relative liver weight).
m-Cresol. Rats were given 0, 50, 150, and 450 mg/kg in a study according to
the aforementioned design (see page 15, gavage study o-cresol by Dietz and
Mulligan (33)), except that microscopical evaluation was performed in the
controls and high dose group only. In the high-dose group, only one male animal
was found dead, but no treatment-related cause could be indicated at necropsy. In
this group, lethargy, tremors, hunched posture, and rough hair coats were
observed frequently post-dosing, and occasionally at the weekly physical
examinations. Furthermore, body weight, body weight gain (both throughout the
experiment), and feed consumption (w 1-4, 6-9, 11) were statistically significantly
decreased in male animals only. The relative brain and absolute liver weights of
the male animals were increased, but this was considered to reflect body weight
gain decreases. No other parameters were changed when compared to controls. In
the mid-dose group, only the male animals were affected: decreased body weight
(w 1-11, 13), body weight gain (w 4-13), and food consumption (w 3, 6, 8, 12,
13), increased relative brain and absolute liver weights (see above. None of these
effects were found in the low dose group (33).
In conclusion, this thirteen-week gavage study using rats resulted in a NOAEL
of 50 mg/kg bw/d for male animals and in a NOAEL of 150 mg/kg bw/d for
female animals.
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The neurotoxicity of m-cresol has been examined according to the design used
to study the neurotoxicity of o-cresol (see page 16, ref 77). Rats were given 0, 50,
150, or 450 mg/kg/d. Mortality was limited to one female animal of the high dose
group dying due to aspiration. There was no effect on body weight. Food
consumption was decreased in the female animals of the high-dose group during
week 1 only and in the male animals of this group during the first three weeks
being statistically significant during week 3 only. At necropsy, there were no
gross or microscopical lesions in the brain or nervous system tissues. There were
no primary compound related effects on the neurobehavioural test parameters. The
observations made within the framework of the neurotoxic examinations showed
increased incidences of urination (before dosing on d 60 and 90) and rales (6 h
after the first dose, before dosing on d 7) in the female rats of the high-dose group.
At the twice-daily observations, dose-related increases (>5%) in incidences of
salivation, myotonus, urine-wet abdomen, hypoactivity, and rapid aspiration were
seen. The increases were higher in the morning than in the afternoon observations.
These signs were only occasionally present in the lower dose groups (maximum
incidence: 7.9% of the morning observations in the mid-dose showed rapid
respiration) (77).
In conclusion, this thirteen-week gavage neurotoxicity study in rats resulted in a
NOAEL of 150 mg/kg bw/d for both male and female rats.
In a two-generation reproduction study (see Section 6.2.7) in which male and
female F0 rats were exposed for thirteen (male) to about nineteen (female) weeks
by gavage, no clinical signs such as hypoactivity, laboured and audible
respiration, etc., were seen in the parental F0 animals at a dose level of 175 mg/kg
bw/d, while exposure to 450 mg/kg bw/d resulted in mortality and CNS-related
signs of toxicity. In the parental animals of the F1 generation exposed for twenty
weeks, body weight depression was noted in all dose groups (lowest dose: 30
mg/kg bw/d) (61).
In conclusion, in this two-generation reproduction study in which m-cresol was
administered by gavage for thirteen (male) to about nineteen (female) weeks, a
NOAEL of 175 mg/kg bw/d for paternal and maternal F0 toxicity can be derived.
p-Cresol. Rats were given 0, 50, 175, and 600 mg/kg in a study according to the
aforementioned design (see page 15, gavage study o-cresol by Dietz and Mulligan
(32), except that in addition to the control and high-dose groups, microscopical
examination of potential target organs (i.e., kidney, trachea) of the two other dose
groups was performed. In the high-dose group, three female animals died within
the first three treatment days, following tremors, convulsions, and comas in two of
them. Lethargy, tremors, and excessive salivation were observed at all or almost
all weekly physical examinations. In addition, there were occasionally
convulsions and comas. Reductions in body weight (male: w 1-13; female: w 1-8),
body weight gain (male: w 1-13; female: w 1-7, 10, 13), and food consumption
(male: w 1-7, 9; female: w 1, 2, 6) were recorded in the high-dose group, while in
the mid-dose female animals body weight gain was decreased in the first two
weeks of the experiment which was accompanied by a decreased food
consumption. In the female animals, the results of haematology and clinical
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chemistry parameters pointed to a, probably not haemolytic, anaemia. This effect
was dose-related, being statistically significant in the two higher dose groups, and
mild, and there was no evidence for physiological compensatory responses. Slight
effects on the liver were found as indicated by statistically significant increases in
both serum transaminases and cholesterol levels in the high-dose female group;
the relative liver weights were normal. In the male animals, serum cholesterol (not
statistically significant) and total protein (statistically significant) were elevated in
the mid- and high-dose groups, while relative liver weights were increased in the
mid and high (significantly) dose group.
Microscopical examinations did not demonstrate hepatic lesions, but there were
indications of (minimal to mild) chronic nephropathy (not specified) in the male
animals of all experimental groups. The incidences were statistically significantly
increased in the low- (11/20 animals, 55%) and high- (12/20, 60%), but not in the
mid-dose group (7/20, 35%) (controls: 4/20, 20%). Relative kidney weights were
elevated in all dose groups, being statistically significant at the two higher dose
levels. Finally, minimal to mild metaplasia of the tracheal epithelium was noted in
the male and female animals of the high-dose group (34).
In conclusion, this thirteen-week gavage study using rats resulted in a NOAEL
of 50 mg/kg bw/d for both male and female animals.
In a separate study, the neurotoxicity of p-cresol has been examined according
to the design used to study the neurotoxicity of o-cresol (see page 16, ref 77). Rats
were given 0, 50, 150, or 600 mg/kg/d. At 600 mg/kg, mortality was 4/10 male (2
direct compound-related; 2 due to aspiration) and 4/10 female animals (2 due to
inhalation of the compound; 1 due to pulmonary oedema; 1 due to a gavaging
incident). There were no significant toxicologically effects on body weight and
food consumption. At necropsy, there were no gross or microscopical lesions in
the brain or nervous system tissues. There were no primary compound-related
effects on the neurobehavioural test parameters. The observations made within the
framework of the neurotoxic examinations showed increased incidences of some
parameters (lacrimation, palpebral closure, rales, laboured respiration), but only
during the first 24 hours of the experiment. At the twice-daily observations, dose-
related increases (>5%) in incidences of salivation, myotonus, urine-wet
abdomen, hypoactivity, rapid respiration were seen. The increases were higher at
the morning than at the afternoon observations, and consistently present in the
high-dose group only (77).
In conclusion, this thirteen-week gavage neurotoxicity study in rats resulted in a
NOAEL of 175 mg/kg bw/d.
In a two-generation reproduction study (see Section 6.2.7) in which male and
female F0 rats were exposed for thirteen (male) to about nineteen (female) weeks
by gavage, no clinical signs such as hypoactivity, laboured and audible
respiration, etc, were seen in the parental F0 animals at a dose level of 175 mg/kg
bw/d, while exposure to 450 mg/kg bw/d resulted in mortality and a number of
CNS-related clinical signs of toxicity. The parental F1 animals appeared to be
more sensitive since they were affected by exposure to 175 mg/kg bw/d (not by
exposure to 30 mg/kg bw/d) (62).
20
In conclusion, in this two-generation reproduction study in which p-cresol was
administered by gavage for thirteen (male) to about nineteen (female) weeks, a
NOAEL of 175 mg/kg bw/d for paternal and maternal F0 toxicity can be derived.
m/p cresol The toxicity of a 60:40% mixture of m/p-cresol was tested in rats and
mice in a thirteen-week feeding study according to the protocol/design used for o-
cresol (doses in rats: 0, 1880, 3750, 7500, 15,000, 30,000 mg/kg feed ( »  130-2050
mg/kg bw/d); doses in mice: 0, 625, 1250, 2500, 5000, 10 000 mg/kg feed ( »  100-
1600 mg/kg bw/d, extrapolation from ppm to mg/kg bw/d made by the author of
the study based on recorded food consumption and body weights). The possible
target organs, bone marrow (rats), nasal mucosa (rats, mice), thyroid gland (rats),
and uterus (rats) were microscopically examined at lower doses as well. In rats,
treatment did not result in mortality; in the highest dose group, clinical signs, i.e.,
rough hair coats in male and female and thin appearance in female animals, were
seen. In the two highest dose groups, body weight (gain) was depressed accompa-
nied with an initially decreased food intake. The relative brain, kidney, and testis
weights were increased in the two highest, those of the liver in the three highest
dose groups. From clinical chemistry data, deficient hepatocellular function in the
two highest dose groups was concluded. Microscopical evaluation showed nasal
epithelial hyperplasia, varying from minimal in a few animals of the lowest dose
group to moderate to marked in almost all or all animals of the highest dose
group. Thyroid lesions (increased colloid within follicles) were seen in almost all
male animals of the two highest dose groups and in almost all female animals of
the three highest dose groups. There was minimal bone marrow hypocellularity in
more than half of the animals of the highest dose group. Uterine atrophy was
noted in the female animals of this latter group as well as in a few animals of the
next lower group. The irritation of the forestomach and the oesophagus reported in
the 28-day study were not seen in this study. Reproductive endpoints, tested in the
1880, 7500, and 30,000 mg/kg feed groups, were not affected in the male animals.
In the female animals oestrus cycle was lengthened in the 7500 and 30,000 mg/kg
feed groups, but not in the 1880 mg/kg feed group. From this study, 123 mg/kg
bw/d for male and 131 mg/kg bw/d for female is concluded to be the NOAEL.
Effect levels are 241 mg/kg bw/d (increased absolute liver weight) and 509 mg/kg
bw/d (engthened 7500 ppm (i.e., 509 mg/kg/d; lenghtened oestrus cycle; increased
relative and absolute liver weight). In mice, effects were limited to occasional
rough hair coat, decreased mean final body weight (gain), increased relative liver
weight, and nasal irritation (minimal respiratory epithelial hyperplasia). For male
animals, the NOAEL is 402 mg/kg bw/d, while 776 mg/kg bw/d is an effect level
(increased relative and absolute liver weight); for female animals, the respective
dose levels are 923 mg/kg bw/d 1623 mg/kg bw/d; decreased body weight;
increased relative liver weight).
In conclusion, the NOAELs and LOAELs and related effects resulting from the
long-term rat studies are summarised in Table 3.
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Table 3. Summary of subchronic rat studies.
NOAEL
mg/kg bw
LOAEL
mg/kg bw
Effect Remark Ref
ortho male/
female
250 510 increased relative
liver weight
13-w feeding study 35
male/
female
175 600 mortality
CNS depression
13-w gavage study 32
male/
female
175 450 mortality
CNS depression
13/» 19-w gavage, two-
generation reproduction
study, toxicity in F0 adults
80
male/
female
175 450 clinical signs 13-w gavage
neurotoxicity study
77
meta male/
female
175 450 mortality
CNS depression
13/» 19-w gavage two-
generation
reproductionstudy,
toxicity in F0 adults
61
male 50 150 decreased body
weight gain
13-w gavage study 33
female 150 450 clinical signs
male/
female
150 450 clinical signs 13-w gavage
neurotoxicity study
77
para male/
female
175 450 mortality
CNS depression
13/» 19-w gavage, two-
generation reproduction
study, toxicity in F0 adults
62
male   50 175 increased total
protein
13-w gavage study 34
female   50 175 anemia mild
male/
female
175 600 clinical signs 13-w gavage,
neurotoxicity study
77
m/p male 123 241 increased
absolute liver
weight
13-w feeding study 35
female 131 509 lengthened
oestrus cycle,
increased relative
and absolute
liver weight
In addition, feeding the     m- /   p- mixture resulted in nasal irritation in rats and, to a
far lesser extent, in mice. Apart from these irritating effects, there are no
indications that the cresols differ with respect to their toxicity.
Therefore, in rats, 50 mg/kg bw/d, the  NOAEL found in thirteen-week gavage
studies on m- and p-cresol, is considered to be the overall NOAEL for all cresol
isomers or any mixture. In mice, where only o-cresol and a 60:40% mixture of m-
and p-cresol were tested in the diet, no NOAEL can be derived: o-cresol induced
effects (increased relative liver weight in males) at 199 mg/kg bw/d, the lowest
dose tested.
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6.2.5 Toxicity due to chronic exposure and carcinogenicity
No chronic studies (including carcinogenicity studies) using the separate cresol
isomers were found, but some carcinogenicity-related aspects have been
examined.
No forestomach lesions were observed in Wistar rats that had received 2% p-
cresol in the diet (»  1500 mg/kg bw/d) for 90 days (in contrast with 4-
methoxyphenol, hydroxyquinone, t-butylhydroxyquinone, 3-t-butyl-4-
hydroxyanisole) (5). However, when p-cresol was fed to male Syrian golden
hamsters (1.5%, »  1100 mg/kg bw/d) for twenty weeks, mild forestomach
hyperplasia in all and moderate hyperplasia in ten out of fifteen hamsters was
induced. There were no severe hyperplasias or papillomatous lesions; there were
no histopathological changes in pyloric regions or bladder epithelium. Body
weights were higher than those of animals fed a basal diet (212 – 25 vs 203– 23 g);
relative liver weights were increased (4.4 – 0.6 vs 3.3– 0.4 g/100g bw) (50).
After a single, initiating dose of 9,10-dimethyl-1,2-benzanthracene, the separate
cresol isomers promoted papilloma growth in the skin of female Sutter mice when
applied in benzene twice weekly for eleven weeks. Treatment resulted in
relatively high mortality (survival at week 12: 17/27, 14/29, 20/28 for o-, m-, p-
cresol, respectively). o-Cresol was most potent inducing an average number of
papillomas per surviving mouse of 1.35 (m-cresol: 0.93; p-cresol: 0.55). No
carcinomas were observed in any mouse. No papillomas were found in the
benzene control group. In four out of five benzene control groups from parallel
running experiments using other compounds, there were no papillomas either
(16).
o-Cresol modified the carcinogenic effect of benzo(a)pyrene (BaP) on the
forestomach of mice. Simultaneous administration by gavage of 1 mg o-cresol
plus 1 mg BaP to female CC57Br mice, twice weekly, twenty times, increased the
incidence, the multiplicity, and the degree of malignancy of forestomach epithelial
tumours, and shortened latency. When o-cresol (1 mg, twice weekly, 20 doses)
was given before BaP (1 mg, twice weekly, 20 doses), tumour incidence and
tumour multiplicity were not affected; the latency time for benign tumours was
increased, while that for malignant tumours was decreased. The reverse order of
treatment resulted in the formation of benign tumours only, and did not change the
other parameters. Simultaneous treatment with 0.02 mg o-cresol and 1 mg BaP
(twice weekly, 20 doses) had the same result as did treatment with 1 mg BaP
alone. Combined administration of 10 mg o-cresol and 5 mg BaP (twice weekly,
20 doses) induced forestomach tumours in all animals, but with decreased
multiplicity, frequency, and percentage of malignant tumours when compared to
the animals receiving 5 mg BaP only (82, 83).
In conclusion, no studies concerning the carcinogenicity of the cresol isomers
when administered alone or in mixtures of them were found. The isomers and
their mixtures may influence the carcinogenicity of other compounds. Especially
o-cresol showed a potential tumour-promoting activity.
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Table 4. Mutagenicity/genotoxicity of cresols.
assay endpoint o m p mix ref
  in vitro   
S. Typhimurium reverse mutation
-/-1 -/- -/- -/- 9
reverse mutation nd nd nd -/- 35
E. coli prophage induction
-
2 + - nd 39
Syrian hamster SV 40 induction nd nd(+) nd nd 9
kidney cells
L5178Y mouse
lymphoma cells
forward mutation -/- -/- -/- +/(+) 9
rat hepatocytes UDS nd/- nd/- nd nd 9
human peripheral semiconservative/repair nd nd nd(+) nd 9
lymphocytes DNA synthesis
Chinese hamster chromosom aberration +/+ -/- +/+ nd 9
ovary cells SCE +/+ nd nd +/+ 9
cultured human SCE nd/- nd/- nd/- nd 9
fibroblasts
human (healthy/non-
smoking) lymphocytes
SCE nd/- nd/- nd/- nd 53
mouse BALB/
C-3T3 cells
cell transformation -/- -/- nd/+ +/nd 9
Allium cepa chromosome aberration + + + nd 25
  in vivo
Drosophila
melanogaster
sex-linked recessive let - nd - nd 9
mouse (route ?) dominant lethal
chromosom aberration
(bone marrow)
-
nd
nd
-
-
nd
nd
nd
9
9
mouse (route i.p.) SCE (bone marrow,
alveolar macrophages,
regenerating liver cells)
- - - nd 9
mouse (route: oral/
feed)
micronuclei (peripheral
blood erythrocytes)
- nd nd - 35
1
 results of tests with and without metabolic activation, respectively; - negative, + positive,
(+) weakly positive results, nd no data, mix = 1:1:1 mixture
2not reported whether or not metabolic activating systems were added (test results from abstract)
6.2.6 Genotoxicity
A number of genotoxicity data are from unpublished studies submitted to US
EPA. These and other results from testing genotoxicity of the cresol isomers and
of a 1:1:1 mixture as having been reviewed by ATSDR (9) as well as from
additional tests are presented in Table 4.
When positive results were obtained, they were mostly weakly positive. Cresols
induced Sister Chromatid Exchange (SCEs) in Chinese Hamster Ovary (CHO)
cells, but not in human cells, and that a tricresol mixture induced mutations in
mouse lymphoma cells, while the individual isomers did not.
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Conclusion:
o-Cresol is not a bacterial mutagen. It showed clastogenic activity in some
mammalian cell systems (CHO cells, but not in human cells).
There is no evidence for genotoxic activity in vivo.
m-Cresol is not mutagenic in S. typhimurium, but is positive in E. coli. It is
negative in mammalian cell systems.
There is no evidence for genotoxic activity in vivo.
p-Cresol is not a bacterial mutagen. It showed some mutagenic and clastogenic
activity in mammalian cell systems.
There is no evidence for genotoxic activity in vivo.
A 1:1:1 mixture is not a bacterial mutagen. It is mutagenic and clastogenic in
mammalian cell systems.
It did not induce micronuclei in murine erythrocytes following oral
administration.
6.2.7 Reproduction toxicology
o-Cresol. The effects on reproductive function have been examined in studies in
which o-cresol was fed to rats and mice for 28 days or thirteen weeks (see Section
6.2.3 and 6.2.4).
In the 28-day study (dose range: 300-30,000 mg/kg feed; »  25-2500 mg/kg
bw/d), no reproductive tissue weight changes or histopathological changes were
observed in rats. Exposure for thirteen weeks (dose range: 1880-30,000 mg/kg
feed; »  130-2025 mg/kg bw/d) resulted in a dose-related lengthened oestrus cycle,
but this did not reach statistical significance. In female mice giving doses ranging
from 300 to 30,000 mg/kg feed ( »  82-5000 mg/kg bw/d), uterine and ovarian
histopathological changes were seen at the highest dose level, and to a less extent
(uterine atrophy only) in the 10,000 mg/kg feed group ( »  1670 mg/kg bw/d).
There were no such changes in the 3000 mg/kg feed group ( »  763 mg/kg bw/d). In
male mice (dose range: 300-30,000 mg/kg feed; »  66-4480 mg/kg bw/d), no
effects on reproductive tissue weights and histology were noted. Exposure for
thirteen weeks caused a dose-related decrease in cauda epididymal weights, the
decreases being statistically significant at the highest dose tested (dose range:
1250-20,000 mg/kg feed; » 199-2723 mg/kg bw/d). At this dose, relative testis
weights were significantly increased as well. In the female animals, oestrus cycle
was statistically significantly lengthened in the highest dose group (dose range:
1250-20,000 mg/kg feed; »  237-3205 mg/kg bw/d) (35).
In rats exposed by gavage to up to 600 mg/kg bw/d, for thirteen weeks, no
changes in testicular and ovarian weights and histology were found (32).
In a developmental toxicity study, o-cresol was administered by gavage to
pregnant rats (Sprague-Dawley; n=25/group; controls: n=50) at doses of 0, 30,
175, and 450 mg/kg bw/d on gd 6-15. Maternal toxicity (mortality: 4/25;
decreased gestational weight gain; clinical signs) was noted in the high dose
group. No effects on malformation incidence or gestation parameters (number of
ovarian corpora lutea, number of implantation sites, number of viable fetuses,
fetal body weight per litter) were observed, but slight fetotoxicity (increased
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incidence of dilated lateral ventricles in the brain) occurred in the 450 mg/kg dose
group (tremors). Doses of 175 mg/kg bw/d did not induce any effect (77). When
o-cresol was given to rabbits (New Zealand; n=14/group, controls: n=25) at doses
of 0, 5, 50, and 100 mg/kg bw/d on gd 6-18, no maternal toxicity was observed,
apart from some occasional clinical signs such as audible respiration (in 2/14) or
hypoactivity (in 1/14) in the high dose group. In this group, there were some
effects indicative of slight  fetotoxicity (poorly ossified sternebrae, increased
incidence of subepidermal haematoma on the head). No effects were reported
following exposure to 50 mg/kg bw/d (79).
From these data, it is concluded that in rats the NOAEL for both maternal and
developmental toxicity is 175 mg/kg/d; in rabbits, the NOAELs are  more than100
mg/kg bw/d and 50 mg/kg bw/d for maternal and developmental toxicity,
respectively.
In a two-generation study, o-cresol was administered in the diet of rats
(Sprague-Dawley; n=25/sex/group) at concentrations of 0, 30, 175, and 450 mg/kg
bw, five days a week. Following a ten-week pre-breeding exposure period,
animals were mated during three weeks. The resulting first-generation (F1)
animals were given the same doses as were their parents for eleven weeks; the
parent (F0) animals were necropsied (females after weaning). Thereafter, the same
procedure was repeated. The experiment was terminated by euthanising the
second-generation (F2) pups at weaning. Treatment did not produce effects on
reproduction parameters or histology of reproductive organs of any of the parental
groups. Toxicity was observed in the high-dose F0 animals (mortality, clinical
signs, decreased body weight (gain)) and in the high-dose (mortality) and mid-
dose (clinical signs) F1 animals. A reduced body weight in F1 male offspring of
the high-dose group immediately prior to the prebreeding period was suggested to
be a possible effect on the offspring. The NOAEL for parental animals was
concluded to be 30 mg/kg bw/d; the NOAEL for offspring 175 mg/kg bw/d (80).
The reproduction toxicity was tested in mice (CD-1 Swiss; n=20/sex/group;
controls: n=40/sex) using the reproductive assessment by continuous breeding
protocol. They were fed 0, 0.05, 0.2, and 0.5% in the diet for approximately
sixteen weeks (1 w singly housed; 14 w as breeding pairs; 1-3 w additional expo-
sure: holding period, rearing final litter). Feed consumption was determined at
week 1 and 16, showing a not-treatment-related decreased intake in all dose
groups (males 9-16%; females 36-38%), from which a mean daily intake of 66,
263 and 660 mg/kg/d was calculated.This treatment did not significantly affect
reproductive endpoints including initial fertility, mean number of litters per pair,
live litter size, the proportion of pups born alive, or adjusted live pup weight. A
small, significant, but not dose-related increase (2-3 days) in cumulative days to
the fourth (low-dose) and fifth (all dose groups) litter was seen. Additional
exposure was considered necessary to evaluate whether this finding will be of
biological significance. In the male animals, spermatoid concentrations were
decreased in the mid-dose group, but increased in the high-dose group. Because of
the lack of a dose-dependence and its absence in the male animals of the
subsequent part of the study, these changes were not considered to be treatment-
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related. At necropsy of the parent animals, there were neither absolute body
weight, nor absolute or relative organ (liver, kidney, testis) weight changes, apart
from decreased absolute kidney weights in the female animals of the high-dose
group. Testicular histology was normal.
In the subsequent part of the study, animals born after week 15 were given the
same doses as were their parents until sexual maturity (74 –  10 d). Twenty control
animals and twenty high-dose animals of each sex (F1 generation) were randomly
assigned to breeding pairs to cohabit for seven days or until a vaginal plug was
found. Then, animals were separated, singly housed, and the experiment was
terminated after delivery of all litters. This exposure (calculated to be 773 and
1128 mg/kg bw/d for males and females of the high-dose group, respectively) did
not affect the mating, fertility, and reproductive performance of the F1 generation,
except for decreased adjusted pup weights (males, females, and combined). In the
male F1 animals, no changes in body weight (apart from one occasion at postnatal
d 74), organ (liver, kidney, epididymis, prostate, seminal vesicles, testis) weights,
sperm parameters, or histology (apart from an equivocally treatment-related
hydronephrosis in 5/19 vs 0/19 in controls) were seen. In the female animals, there
was no effect on organ weights, vaginal cytology, or histology (liver, kidney,
ovary); body weight was decreased at postnatal days 21 and 74 (not at d 84 and
112 and postpartum) and at necropsy. The NOAEL for reproduction as well as
general toxicity in this study was concluded to be 0.2% or 263 mg/kg bw/d (42).
m-Cresol. In a 28-day study in which rats were given up to 30,000 ppm m-
cresol in the diet (male: »  2470 mg/kg bw/d, female: »  2310 mg/kg bw/d), no
reproductive tissue weight or histopathological changes were observed in the male
rats. In the female rats, microscopical evaluation showed uterine atrophy in the
highest dose group, but not in the 10,000 mg/kg feed group ( »  862 mg/kg bw/d).
When administered to mice, relevant parameters were not affected in male
animals fed up to 30,000 mg/kg feed ( »  4710 mg/kg bw/d). As in females, uterine,
ovarian, and mammary gland histopathological changes were seen in the 30,000
mg/kg feed group (»  4940 mg/kg bw/d), but not in the 10,000 mg/kg feed group
(»  2080 mg/kg bw/d) (see also Section 6.2.3) (35).
In rats exposed by gavage up to 450 mg/kg bw/d, for thirteen weeks, no changes
in testicular and ovarian weights and histology were found (33).
In a developmental toxicity study, m-cresol was administered by gavage to
pregnant rats (Sprague-Dawley; n=25/group; controls: n=50) at doses of 0, 30,
175, and 450 mg/kg bw/d on gd 6-15. Maternal toxicity (decreased gestational
weight gain; increased relative liver weight; clinical signs) was noted in the high
dose group. There were no effects on malformation incidence or gestation
parameters and no fetotoxicity (77). When given to rabbits (New Zealand;
n=14/group; controls: n=25) at doses of 0, 5, 50, and 100 mg/kg bw/d on gd 6-18,
neither maternal nor developmental toxicity were observed in any of the dose
groups (79).
From these data, it is concluded that in rats the NOAELs are 175 and more than
450 mg/kg bw/d for maternal and developmental toxicity, respectively; in rabbits,
the NOAEL is 100 mg/kg bw/d for both maternal and developmental toxicity.
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In a two-generation study, m-cresol was tested in rats according to the same
protocol/study design as was o-cresol (see page 25). Treatment did not cause
changes in reproductive parameters or histology of reproductive organs in any of
the parental groups. Parental toxicity occurred in the high-dose F0 animals as well
as in all dose groups of the F1 generation adults. Indications of toxicity in the F1
and F2 offspring were noted in the high-dose group. The NOAEL for parental
animals was concluded to be lower than 30 mg/kg/d (i.e., lowest dose tested), that
for the offspring 175 mg/kg bw/d (61).
p-Cresol. Given up to 30,000 mg p-cresol/kg feed in the diet for 28 days
resulted in increased relative testis weights, which were considered to reflect the
depressed body weight gain, in the highest dose group. In the female animals,
histopathological uterine changes were observed in the 30,000 mg/kg feed group
(»  2060 mg/kg bw/d), but not in the 10,000 mg/kg feed group ( »  764 mg/kg
bw/d). No effects on reproductive endpoints were seen in male and female mice
exposed to up to 30,000 mg/kg feed (see also Section 6.2.3) (35).
In rats exposed by gavage to up to 600 mg/kg/d, for thirteen weeks, no changes
in testicular and ovarian weights and histology were found (34).
No effects on malformation incidence or gestational parameters were reported
to be found following administration by gavage to rats and rabbits during
gestation. At maternally toxic doses of 450 mg/kg bw/d (mortality: 3/14;
increased relative liver weight; clinical signs) slight fetotoxicity (minor skeletal
variations; reduced fetal bw per litter) occurred in rats. Administration of 175
mg/kg bw/d did not induce any effect. In rabbits, maternally toxic doses of 50 and
100 mg/kg bw/d (mortality: 2/14, 5/14, resp) did not induce fetotoxicity (78, 79).
From these data, it is concluded that in rats the NOAEL for both maternal and
developmental toxicity is 175 mg/kg bw/d; in rabbits, the NOAELs are 5 mg/kg
bw/d and  100 mg/kg/d for maternal and developmental toxicity, respectively.
In a two-generation study conducted according to the protocol/study design
used for the two other isomers (see page 25), no effects on reproduction
parameters or histology of reproductive organs were found in any of the parental
groups. Toxicity was seen in the high-dose animals of the F0 generation and in the
mid-dose and high-dose adults of the F1 generation. There were no clear
indications for toxicity in the F0 offspring, but signs of toxicity were observed in
the F2 pups of the high-dose group. The NOAEL for parental animals was
concluded to be 30 mg/kg/d, that for offspring 175 mg/kg bw/d (62).
m/p-Cresol. The effects of exposure to a mixture (60:40%) of m- and p-cresol
on the reproductive organs of rats and mice have been investigated.
Administration of up to 30,000 mg/kg in the diet for 28 days increased relative
testis weights, considered to reflect body weight gain depression, in the 30,000
mg/kg feed group (daily dose: 2600 mg/kg bw/d). There were no effects in the
female animals (highest dose: 2570 mg/kg bw/d). Exposure for thirteen weeks
significantly increased testis weights in the 15,000 mg/kg feed(991 mg/kg bw/d)
and 30,000 mg/kg feed ( »  2014 mg/kg bw/d), but not in the 7500 mg/kg feed ( »
486 mg/kg bw/d) group. There were no changes in absolute reproductive tissue
weights and spermatozoal characteristics. In female rats, uterine atrophy was
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observed in the 15,000 mg/kg feed ( » 1024 mg/kg bw/d) and 30,000 mg/kg feed ( »
2050 mg/kg bw/d), but not in the 7500 mg/kg feed ( »  509 mg/kg bw/d) group. In
these dose groups (except for the 15,000 mg/kg feed group: not tested), a dose-
related increase in the oestrus cycle occurred (not at 1880 mg/kg feed; »  131
mg/kg bw/d). In mice, treatment for 28 days resulted in increased relative testis
weights in the male and in uterine and ovarian athrophy in the female animals of
the highest dose group (daily doses: 4530 and 4730 mg/kg feed, respectively).
Treatment for thirteen weeks did not affect the reproductive endpoints under study
(highest dose tested: 10,000 mg/kg feed. (35).
The reproduction toxicity of this m-/p-cresol mixture was tested in mice (CD-1
Swiss; n=20/sex/ group; controls: n=40 per sex) using the reproductive assessment
by continuous breeding protocol as well (see o-cresol, page 25). They were fed 0,
0.25, 0.5, and 1.5% (calculated to be 362, 1389, and 1682 mg/kg bw/d) in the diet
for approximately sixteen weeks (1 w singly housed; 14 w as breeding pairs; 1-3
w additional exposure: holding period, cross-over mating trial, rearing final litter).
Treatment caused dose-related decreases in body weights of the F0 male animals
at week 1 and week 16 and of the female F0 animals at week 16, being statistically
significant in the high-dose group. Measurements of dam body weights at delivery
showed dose-related decreases as well, being statistically significant for all five
litters in the high-dose group, for the first and third litters in the mid-dose group,
and for the fifth litter in the low-dose group. A similar picture emerged when
measuring body weights of dams lactating their final litter (i.e., dose-related
decreases, statistitically significant at day 0, 4, 7, 14, and 21 in the high-dose
group, at day 0, 4, 7, 14 in the mid-dose group, at day 0, 14 in the low-dose
group). Other signs of toxicity in the F0 animals included increased relative female
(all dose groups) and male (mid-, high-dose group) liver and male (mid-, high-
dose group) kidney weights. Toxicity of reproductive organs was observed in the
male animals of the high-dose group in the form of decreased epididymal and
seminal vesicle weights, but there were no changes in testis weights, sperm
parameters, and testicular and epididymal histology. Reproductive endpoints
including initial fertility, the proportion of pups born alive, or the sex of pups born
alive, were not significantly affected, but in the high-dose group adjusted live pup
weight and the number of live pups per litter were decreased (by 5 and 20%, resp).
In addition, a significant increase in cumulative days to litter was seen for litters 2
through 5 (being almost three days at litter 5). Finally, in the high-dose group,
preweaning growth and postweaning survival were decreased by 26% and 39%,
respectively.
In the subsequent part of the study, animals born after week 15 were given the
same doses as were their parents until sexual maturity (74 –  10 d). Twenty control
animals of each sex and twenty animals of each sex of each treatment group (F1
generation) were randomly assigned to breeding pairs to cohabit for seven days or
until a vaginal plug was found. Then, animals were separated, singly housed, and
the experiment was terminated after delivery of all litters. This exposure did not
affect the mating, fertility, and reproductive performance of the F1 generation,
except for decreased adjusted pup weights (males, females, and combined) in the
29
high-dose group (dose calculated to be 2490 and 2939 mg/kg bw/d for males and
females, respectively). Parental toxicity included treatment-related clinical signs
(in the animals of the high-dose group), decreased body weights (in all dose
groups at postnatal day 74; in the mid- and high-dose group at the end of
experiment), and relative organ weight changes (amongst others increased liver
weight and increased ovary weight in the females of all dose groups; increased
liver weights, decreased prostate and seminal vehicle weights in the males of the
mid- and high-dose groups), but there were no effects on sperm parameters, length
of estrous cycle, or organ histology (apart from an equivocal treatment-related
renal hydronephrosis in high-dose males (52). The NOAEL for parental animals is
concluded to be < 0.25% or 362 mg/kg bw/d, that for offspring 1389 mg/kg bw/d.
In conclusion, the oral administration of the cresol isomers to rats, rabbits, or
mice did not affect malformation incidence and gestational or developmental
parameters. At maternally toxic doses, slight fetotoxicity was observed. Changes
in male reproductive tissue weights and female reproductive tissue histology and
increases in oestrus cycle were seen at relatively high doses (more than »  500
mg/kg bw/d).
6.3 Other studies
The in vitro toxicity (measured as lactate dehydrogenase (LDH) leakage from
tissue into incubation medium) of the cresol isomers has been compared using rat
liver slices. At equimolar concentrations, p-cresol was the most toxic compound;
a five- to ten-fold of either o- or m-isomers was required to produce the same
degree of effect. The toxicity of p-cresol (but hardly that of the other isomers) was
influenced by adding a thiol precursor (decrease) or a glutathione-depleting agent
(increase). These and other experiments, using rat liver microsomes, suggested
that the mechanism of this in vitro toxicity of p-cresol may differ from that of the
other isomers, and that a reactive intermediate (a quinone methide) is involved
(75, 76).
6.4 Summary
6.4.1 Human data
In a Russian study of unkown design, brief exposures to 6 mg/m3 (1.4 ppm)
caused mucosal irritation in the majority of the volunteers exposed.
Liquid cresols may result in severe skin irritation and dermatitis and a variety of
systemic effects including coma and death.
No data on effects due to occupational exposure from valid studies were found.
6.4.2 Animal data
The cresol isomers are strong eye and skin irritating compounds. p-Cresol did not
induce sensitisation in guinea pigs.
Russian studies did not allow a proper assessment of toxicity following
inhalatory exposure as exposure data were lacking; however, these studies suggest
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that long-term exposure to relatively low levels of cresols, 5-10 mg/m3, may affect
animal health.
From single exposure data, it may be concluded that the cresol isomers are more
toxic when administered via the dermal route than via the oral route. Following
repeated oral exposure, there are no indications that there are differences between
systemic effects of the separate isomers and a 60:40% mixture of m- and p-cresol.
Minimal to moderate local irritating effects were induced by feeding p-cresol
(nasal epithelium) and a 60:40% mixture of m- and p-cresol (nasal epithelium;
oesophagus, and the forestomach (seen in a 28-d, but not in a 13-w study)) to both
rats and mice.
In 28-day feeding studies, effects on liver and kidney weights, not accompanied
with histopathological changes, were observed in rats and mice. In rats, the
NOAEL was 27 mg/kg bw/d, while in mice a NOAEL could not be established,
but will be lower than 60 mg/kg bw/d.
o-Cresol and a 60:40% mixture of m- and p-cresol were tested in thirteen-week
feeding studies. Similar effects were noted, but the mixture also caused lengtening
of the oestrus cycle. In rats, the NOAEL was 129 mg/kg bw/d, but in mice
exposed to o-cresol, effects still occurred at 199 mg/kg bw/d), the lowest dose
tested.
In thirteen-week gavage studies, performed in rats only, CNS-related effects
and mortality were seen in high dose groups (450 or 600 mg/kg/d; depending on
isomer tested). In lower dose groups, decreased body weight gain (male, m-cresol,
150 mg/kg), mild anaemia (female, p-cresol, 175 mg/kg) and increased total
protein (males, p-cresol, 175 mg/kg) were seen. There were no changes in neuro-
behavioural parameters or in brain and nervous tissue histology. The NOAEL
from these studies is 50 mg/kg bw/d.
Parental animal examinations in two-generation reproduction studies (gavage;
exposure time: 13-20 weeks) showed similar CNS-related effects as well as
mortality in the high-dose group (450 mg/kg bw/d) of the F0 adults frequently, but
not in the mid-dose group (175 mg/kg bw/d). In parental animals of the F1
generation, administration of 30 mg/kg bw/d resulted in decreased body weights
(gain).
There were no life-time carcinogenicity studies. p-Cresol induced mild to
moderate hyperplasias (but no papillomatous lesions) in the forestomach of
hamsters when fed in the diet for twenty weeks, but not in rats (90-day exposure).
o-Cresol and, to a lesser extent, m- and p-cresol promoted papilloma growth when
applied on mouse skin, pretreated with a carcinogen.
The cresols (isomers; 1:1:1 mixture) did not show genotoxic activity in vivo or
in gene mutation tests in bacteria in vitro. o-Cresol is clastogenic, while p-cresol
has a somewhat broader activity; the 1:1:1 mixture showed an activity similar to
those of the latter isomers.
In developmental toxicity and two-generation reproduction studies, oral
administration of the cresol isomers did not affect malformation incidence and
gestational and developmental parameters at doses that were not maternally toxic.
31
7. Existing guidelines, standards, and evaluations
7.1 General population
In some states of the US, ambient air limits for cresols or specific isomers have
been established. Depending on the state, eight-hour limits of cresols are 200, 220,
or 524 m g/m3 (44, 48, 115 ppb). In addition, 24-hour limits of 12 mg/m3 (3 ppb)
for p-cresol, 220 mg/m3 (48 ppb) for cresols, and 370 mg/m3 (81 ppb) for cresol
isomers and a one-year limit of 73 mg/m3 (16 ppb) for cresols and isomers are
reported (9).EPA has derived a reference dose for lifetime exposure to cresols of
0.05 mg/kg bw/d (9).
The Commission of the European Communities has classified the cresol
isomers and their mixtures at concentrations  5% as toxic in contact with skin and
if swallowed and as corrosive, causing burns (labelled with R(isk)-phrases 24/25
and 34). At concentrations between 1 and 5%, they are classified as harmful in
contact with skin and if swallowed and irritating to eyes and skin (R-phrases
21/22 and 36/38). Wearing suitable protective clothing, gloves, and eye/face
protection is recommended (21).
7.2 Working population
7.2.1 Occupational exposure limits
Occupational exposure limits in The Netherlands and in some other countries are
presented in Table 5. These limits apply to the individual isomers or to any
mixture of the isomers.
In Germany, the MAK value for cresol isomers is 22 mg/m3 (5 ppm). However,
in a recent re-evaluation (not yet published) of this limit, the DGF-MAK
committee concludes that it is not possible to derive a health based occupational
exposure limit. Although a NOAEL (derived from a subchronic oral study) could
Table 5. Occupational exposure limits in The Netherlands and in some other countries.
country concentration    time relation skin
notation
reference
ppm mg/m3
The Netherlands  5   22 8-h TWA + 51
Danmark  5   22 8-h TWA + 8
Germany  5
10
  22
  44
8-h TWA
5-min ceiling
8 times/workday
+ 31
Norway  5   22 8-h TWA + 36
UK  5   22 8-h TWA + 45
US-ACGIH  5   22 8-h TWA + 2
    -NIOSH  2.3   10 10-h TWA 20
    -OSHA  5   22 8-h TWA + 4
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be determined, the DFG-MAK committee feels that irritation and systemic effects
following inhalation exposure are the critical effects.
7.2.2 Biological limit values
No biological limit values have been established.
7.3 Evaluations
ACGIH concludes that there are no relevant quantitative toxicity data. The
recommended occupational exposure limit of 5 ppm is based on closely analogous
toxic action to phenol (1).
NIOSH feels that the greatest hazard from exposure to cresols results from skin
and eye contact. It was concluded that exposure to cresols can produce effects on
the central nervous system, the respiratory system, the liver, the kidneys, the
pancreas, the vascular system, and the eyes. Furthermore, the similarity between
the exposure routes, absorption, and the toxicity of the cresol isomers and phenol
was noted. Despite flaws in the studies available to and discussed by NIOSH,
there was sufficient agreement between findings showing adverse effects in
humans and animals at concentrations below 20 mg/m3 (4.6 ppm). Therefore, a
limit of 10 mg/m3 (2.3 ppm) (10-h TWA, for a 40-h workweek) was
recommended.
This was believed to protect workers from impairment of motor function and
from damage to the liver, kidneys, and pancreas, and to reduce the probability of
cresol acting as a tumour promotor (64).
8. Hazard assessment
8.1 Assessment of health hazard
Concentrated aerosols and vapour concentrations of 6 mg/m3 (1.4 ppm) were
reported to cause irritation in humans, but because of lack of details thisdata
cannot be evaluated properly. The results of the oral animal toxicity studies as
presented in Sections 6.2.3 to 6.2.6 do not clearly indicate significant differences
with respect to the toxicity of the separate isomers.
Especially o- and p-cresol were found to be genotoxic in in vitro mammalian
cell systems, but none of the cresols showed genotoxicity in in vivo systems
(mouse, Drosophila). The observed in vitro genotoxicity might be due to
metabolic formation of reactive intermediates like epoxide; quinone methide; This
mechanism has been suggestedespecially to explain the data for p-cresol in vitro
experiments using rat liver preparations. In rabbits, metabolites resulting from
these intermediates were found in the urine in only limited amounts. There are no
data on the metabolism of cresols in other species, including man. However, based
on the negative in vivo genotoxicity tests, and assuming that detoxifying and
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conjugating mechanisms are efficiently trapping these intermediates, the cresols
probably do not pose a genotoxic hazard in humans.
There are no data from experimental lifetime carcinogenicity studies, but there
are indications that o-cresol has a tumour-promoting activity. NTP (National
Toxicology Program) has selected o-cresol and an m-/p-cresol mixture for
comparative chronic toxicity and carcinogenesis studies in rats and mice (65).
Animal studies showed that the liquid cresol isomers are irritating to the eyes
and skin of rabbits. Especially nasal irritation was seen in rats and mice fed with
p-cresol and a mixture of m- and p-cresol, probably as a result of direct contact of
the nose with these compounds in the feed or with cresol vapour emanating from
the feed. Irritation from exposure to vapours has been reported to occur in rats,
mice, and cats, but these reports contain serious flaws and cannot be properly
evaluated.
Data from experimental inhalatory studies are insufficient to assess the
inhalation toxicity, but do suggest that short-term exposure to relatively low levels
of 5-10 mg/m3 may effect animal health.
The toxicity of the cresol isomers has been adequately tested via the oral route
only. Reproduction and teratogenicity studies showed that the cresols are not
reproductive or developmental toxicants, and do not induce irreversible structural
effects. Changes in male reproductive organ weights, in female reproductive
tissue histology, and increases in oestrus cycle were seen at relatively high doses
exceeding 500 mg/kg bw/d).
Feeding rats cresols at doses up to approximately 2000 mg/kg bw/d for 90 days
did not result in mortality or overt toxicity, but induced mainly slight effects on
the liver. Giving cresols by gavage induced mortality at doses of approximately
600 mg/kg bw/d and transient CNS-related clinical signs at doses of 450 mg/kg
bw/d, but had no effect on organ weights. As concluded in Section 6.2.4, 50
mg/kg bw/d is the NOAEL for subchronic administration of any cresol isomers or
mixture of isomers.
Based on the available data the critical effect of exposure to cresol is irritative
effects.
8.2 Groups at extra risk
No groups at extra risks could be identified from the available literature.
9. Recommendations for research
-  a 90-day inhalation toxicity study in rats
-  in vivo metabolism studies in rats
-  estimating human metabolism by comparing in vivo rat data with those
-  from relevant in vitro rat and human systems
34
10. Summary
Stouten H. Cresols (o-, m-, p-). DECOS and SCG Basis for an Occupational
Standard. Arbete och Hälsa 1998;27:1-44.
Cresols occur as crystalline solid to colourless to yellowish liquid. They are
slightly soluble in water and soluble in organic solvents. There are no data on the
absorption of cresols in humans. In vivo animal data indicate that most of the
administered dose (gavage) is absorbed and excreted in the urine, mainly as
conjugates. The oxidative metabolism of p-cresol in rat liver microsomes proceeds
differently from that of the other isomers. The critical effect of cresol vapours is
local irritation.
Keywords: Cresols, Hazard assessment, Irritation, Occupational Exposure limit,
Toxicity
11. Summary in Swedish
Stouten H. Cresols (o-, m-, p-). DECOS and SCG Basis for an Occupational
Standard. Arbete och Hälsa 1998;27:1-44.
Kresoler förekommer i fast kristallin form och/eller färglös till gulaktig vätska. De
är svagt lösliga i vatten och lösliga i organiska lösningsmedel. Det saknas data
över absorption av kresoler hos människa. Djurdata in vivo antyder att
huvudparten av administrerad dos (magsond) absorberas och utsöndras i urin,
huvudsakligen som konjugat. Metabolismen av p-kresol i mikrosomer från
råttlever skiljer sig från de andra isomerernas metabolism. Den kritiska effekten
av kresolånga är irritation.
Nyckelord: Hygieniskt gränsvärde, Irritation, Kresoler, Riskbedömning, Toxicitet.
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Annex
Effects of short-term exposure to cresols (from ref 35)
speciesa dose/timeb effectsc
   o-cresol
F344/N rat
(5)/sex
300-30000 ppm
in diet
(males: 27-2610,
females: 27-2510
mg/kg/d) for 28
days
no deaths; no clinical signs of toxicity; no gross lesions; no histo-
pathological changes.
30,000 ppm (male:2610, female 2510 mg/kg/d): decreases in food
consumption during first week by 50-60% (male, female), in mean
final body weight (female); in mean body weight gain (male,
female). Increases in absolute liver weight (male, female), in
relative liver weight (male), in absolute kidney weight (male), in
relative kidney weight (male), in relative brain weight (female).
10,000 ppm (male: 861, female: 881 mg/kg/d): increases in
absolute (male, female) and relative (male, female) liver weight, in
absolute (male) and relative (male) kidney weight.
3000 ppm (male: 266, female: 271 mg/kg/d): increases in relative
liver and kidney weight (male).
B6C3F1
mouse
(5)/sex
300-30000 ppm
in diet
(male: 66-4480,
female: 82-5000
mg/kg/d) for 28
days
no gross lesions.
30,000 ppm (male: 4480, female 5000 mg/kg/d): two males and
one female died or sacrificed moribund (no histopathological
changes). Clinical signs of toxicity: hunched posture, lethargy,
rough hair coat, thin appearance (male, female), hypothermia,
rapid breathing, tremors (male). Decreased feed consumption
during first week (male, female). Weight loss in surviving animals.
Decreases in mean final body weight (male, female), in mean body
weight gain (male, female). Increases in relative liver weight
(male, female), in relative (male) kidney weight, in relative brain
weight (female); decrease in absolute kidney weight (female) and
absolute brain weight (female). Mild ovarian (3/5 female) and
moderate uterine (4/5 female) atrophy.
10,000 ppm (male: 1650, female 1670 mg/kg/d): decreases in feed
consumption in first three days (male); in mean body weight gain
(male, female). Increases in relative liver weight (male, female), in
relative kidney weight (male, female). Mild uterine atrophy (5/5
female).
3000 ppm (male: 558, female: 763 mg/kg/d): increase in relative
liver weight (male, female).
Cont.
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Cont.
speciesa dose/timeb effectsc
    m-cresol  
F344/N rat
(5)/sex
300-30000 ppm
in diet
(males: 25-2470,
females: 25-2310
mg/kg/d) for 28
days
no deaths; no clinical signs of toxicity; no gross lesions.
30,000 ppm (male: 2470, female: 2310 mg/kg/d): decreases in feed
consumption by 40-50% in the first week (male, female), in mean
final body weight (male, female); in mean final body weight gain
(male, female). Increase in relative liver (male, female), in relative
kidney weight (male, female), in relative brain weight (male,
female); decrease in absolute brain weight (female). Minimal to
mild uterine atrophy (reduced uterine horn cross-sectional
diameter and stromal and smooth muscle cells sizes) (4/5 female).
10,000 ppm (male: 870, female: 862 mg/kg/d): increase in
absolute (male) and relative (male, female) liver weights.
B6C3F1
mouse
(5)/sex
300-30000 ppm
in diet
(males: 53-4710,
females: 66-4940
mg/kg/d) for 28
days
no gross lesions. (one control animal dead)
30,000 ppm (male: 4710, female: 4940 mg/kg/d): two per sex died
or were sacrificed moribund (no histopathological changes).
Clinical signs of toxicity: hunched posture, rough hair coat, thin
appearance, lethargy, tremors (male, female), hypothermia
(female). Weight loss in surviving animals. Decrease in feed
consumption (male during first week; female during first and third
week), in mean final body weight (male, female), in mean final
body weight gain (male). Increase in relative liver weight (male,
female), in relative kidney weight (male), in relative brain weight
(male). Mild to moderate mammary gland (3/5 female), mild
ovarian (3/5 female), moderate uterine (3/5 female) atrophy.
10,000 ppm (male: 1730, female 2080 mg/kg/d): one female dead
(no histopathological changes). Clinical signs: hunched posture,
rough hair coat (male, female), labourated breathing, lethargy,
sunken eyes (female). Increases in relative liver weight (male,
female).
3000 ppm (male: 521, female: 651 mg/kg/d): increases in relative
liver weight (male, female), in relative kidney weight (male).
1000 ppm (male: 193, female: 210 mg/kg/d): increase in relative
liver weight (female).
300 ppm (male: 53, female: 66 mg/kg/d): increase in relative liver
weight (female): thin appearance.
Cont.
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speciesa dose/timeb effectsc
   p-cresol
F344/N rat
(5)/sex
300-30000 ppm
in diet
(males: 25-2180,
females: 25-2060
mg/kg/d) for 28
days
no deaths; no gross lesions.
30,000 ppm (male: 2180, female: 2060 mg/kg/d): clinical signs of
toxicity: hunched posture, rough hair coat, thin appearance (during first
week; male, female). Decrease in feed consumption by almost 80%
(first week: male, female), in mean final body weight and in mean final
body weight gain (male, female). Increase in relative liver weight (male,
female), in relative kidney weight (male, female), in relative brain
weight (male, female), in relative testis weight; decrease in absolute
brain weight (male). Histopathological changes: moderate bone marrow
hypocellularity (5/5 male, 3/5 female), mild olfactory epithelial atrophy
(5/5 male, 4/5 female); respiratory epithelial hyperplasia (mild to
moderate: 5/5 male, 3/5 female) and squamous metaplasia (mild: 2/5
male). Mild to moderate uterine atrophy (reduced uterine horn diameter
and stromal and smooth muscle cell size) (3/5 female).
10,000 ppm (male: 835, female: 769 mg/kg/d): increase in relative liver
weight (male, female); in relative kidney weight (male).
Histopathological changes: mild hypocellularity (1/5 male, 1/5 female);
respiratory epithelial hyperplasia (moderate: 4/5 male, 3/5 female) and
squamous metaplasia (mild: 1/5 female).
3000 ppm (male: 256, female: 242 mg/kg/d): increase in relative and
absolute liver weight (female). Histopathological changes: mild bone
marrow hypocellularity (1/5 male); minimal olfactory epithelial atrophy
(1/5 female); minimal respiratory epithelial hyperplasia (1/5 male, 1/5
female).
B6C3F1
mouse
(5)/sex
300-30000 ppm
in diet for 28
days
no gross lesions.
30,000 ppm: all animals died or were sacrificed moribund (9/10 within
first 5 days) after clinical signs of toxicity: hunched posture, rough hair
coat, lethargy, hypothermia, thin appearance. Histopathological changes
in several organs/tissues (bone marrow, kidney, liver, nasal cavity,
lymphoid tissues).
10,000 ppm(male: 1410, female 1590 mg/kg/d): one male dead. Clinical
signs: hunched posture, rough hair coat, lethargy, hypo-thermia,
laboured respiration, paleness, thin appearance (male). Decrease in feed
consumption first two weeks (male, female), in mean body weight
(male), in mean final body weight gain (male). Increase in absolute
(female) and relative (male, female) liver weight; in relative kidney
weight (male), in relative heart weight (male); decrease in absolute brain
weight (female). Histopathology: mild olfactory epithelial squamous
metaplasia (2/5 male), respiratory epithelial hyperplasia (minimal to
mild; 5/5 male, 5/5 female) and squamous metaplasia (mild; 2/5 male).
3000 ppm (male: 469, female: 564 mg/kg/d): increase in relative liver
weight (female), in relative kidney weight (male); decrease in absolute
brain weight (female). Histopathology: minimal olfactory epithelial
atrophy (1/5 female), minimal to mild respiratory epithelial hyperplasia
(5/5 male, 4/5 female).
1000 ppm (male: 163, female: 207 mg/kg/d): decrease in absolute brain
weight (female). Histopathology: minimal respiratory epithelial
hyperplasia (3/5 male, 2/5 female).
300 ppm (male: 50, female: 60 mg/kg/d): histopathology: minimal
respiratory epithelial hyperplasia (1/5 female).
Cont.
43
Cont.
speciesa dose/timeb effectsc
    m/p-cresol  
(60:40
mixture)
F344/N rat
(5)/sex
300-30000 ppm
in diet
(males: 26-2600,
females: 27-2527
mg/kg/d) for 28
days
no deaths; no gross lesions.
30,000 ppm (male: 2600, female: 2570 mg/kg/d): clinical signs:
thin appearance in first week (male, female). Decrease in feed
consumption by approx 75 % during first week (male, female), in
mean final body weight (male, female), in mean final body weight
gain (male, female). Increase in absolute (female) and relative
(male, female) liver weight, in absolute (females) and relative
(male, female) kidney weight, in relative brain weight (male), in
relative testis weight. Histopathology: minimal bone marrow
hypocellularity (3/5 male, 5/5 female), minimal to mild
oesophagus epithelial hyperkeratosis and hyperplasia (5/5 male,
5/5 female), minimal to mild forestomach epithelial hyperkeratosis
(5/5 female) and hyperplasia (5/5 male, 5/5 female), Increased
colloid follicles (minimal to mild in 5/5 male, moderate to marked
in 4/5 females), moderate to marked respiratory epithelial
hyperplasia (5/5 male, 4/5 female).
10.000 ppm (male: 877, female: 886 mg/kg/d): increase in
absolute and relative liver weight (male, female), in absolute
(female) and relative (male, female) kidney weight.
Histopathology: minimal bone marrow hypocellularity (1/5
female), minimal oesophagus epithelial hyperkeratosis and
hyperplasia (4/5 male, 3/5 female), minimal forestomach epithelial
hyperkeratosis (4/5 male, 3/5 female) and hyperplasia (2/5 male,
2/5 female), minimal to mild increased colloid within thyroid
follicles (5/5 male, 5/5 female), respiratory epithelial hyperplasia
(mild to moderate in 5/5 male, minimal in 5/5 female).
3000 ppm (male: 261, female: 268 mg/kg/d): increase in relative
liver weight (male, female). Histopathology: minimal oesophagus
epithelial hyperkeratosis (3/5 male, 2/5 female) and hyperplasia
(3/5 male, 3/5 female), minimal increased colloid within thyroid
follicles 3/5 male, 4/5 female), respiratory epithelial hyperplasia
(mild in 5/5 male, minimal in 4/5 female).
1000 ppm (male: 90, female: 95 mg/kg/d): increase in absolute and
relative liver weight (female). Histopathology: minimal respiratory
epithelial hyperplasia (3/4 female).
Cont.
44
Cont.
speciesa dose/timeb effectsc
B6C3F1
mouse
(5)/sex
300-30000 ppm
in diet
(males: 50-4530,
females: 65-4730
mg/kg/d) for 28
days
no deaths, no gross lesions.
30,000 ppm (male: 4530, female: 4730 mg/kg/d): clinical signs:
hunched posture, rough hair coat, lethargy, hypothermia, thin
appearance, alopecia, dehydration (male, female). Weight loss
(male, female). Decreases in feed consumption (male during first
week, female during week 1 and 3), in mean final body weight
(male, female), mean final body weight gain (male, female), in
absolute kidney weight (male), in absolute brain weight (male,
female). Increase in absolute (female) and relative (male, female)
liver weight, in relative kidney weight (female) in relative brain
weight (male, female), in relative testis weight. Histopathology:
minimal to mild bone marrow cellularity (2/5 male, 1/5 female),
minimal oesophagus epithelial hyperkeratosis and hyperplasia (1/5
female), minimal forestomach squamous epithelial hyperplasia
(1/5 male); minimal bronchiolar hyperplasia (5/5 male, 5/5
female), mild ovarian (1/5 female) and moderate uterine (1/5
female) atrophy, minimal to mild respiratory epithelial hyperplasia
(5/5 male, 4/5 female), minimal olfactory epithelial atrophy (2/5
male); minimal to mild olfactory epithelial respiratory metaplasia
(3/5 male, 2/5 female).
10 000 ppm (male: 1490, female: 1880 mg/kg/d): decreased mean
final body weight gain (male). Increases in absolute (female) and
relative (male, female) liver weight. Histopathology: minimal to
mild respiratory epithelial hyperplasia (1/5 male, 3/5 female).
3000 ppm (male: 471, female: 604 mg/kg/d): increased absolute
(female) and relative liver weight (male, female). Histopathology:
minimal respiratory epithelial hyperplasia (3/5 female).
1000 ppm (male: 161, female: 200 mg/kg/d): increased relative
liver weight (male).
a
 number between parenthesis represent the number of animals exposed per sex per group.
b
 extrapolation from ppm to mg/kg bw/d as presented and calculated, based on recorded food
  consumption and body weights, by Dietz (35).
c
 only those parameters that differ statistically significantly from those in controls (p£ 0.01 or
  £ 0.05)
